Researchers at The Royal Marsden, partnering with Guardant Health, have developed a groundbreaking liquid biopsy test called Marsden360. This simple blood test offers significant advantages for lung cancer patients, the Third Most Common and Serious Cancer in the UK.
Minimally Invasive Test Detects Cancer DNA
Marsden360 utilizes circulating tumor DNA (ctDNA) shed by lung cancer cells. This eliminates the need for traditional, potentially risky tissue biopsies. The ctDNA analysis reveals the unique genetic makeup of the cancer, enabling doctors to create Personalized Treatment Plans.
Early Success and National Expansion
Over 2,000 patients have already benefitted from Marsden360, and NHS England is expanding access to 10,000 more patients this year. This large-scale rollout aims to solidify the role of liquid biopsies in Improving Lung Cancer Care Nationwide.
Experts Optimistic About Future Impact
Professor Sanjay Popat of The Royal Marsden highlights the test’s ability to “significantly increase research capacity” and ultimately lead to “improved treatment options.” Helmy Eltoukhy of Guardant Health emphasizes the potential for Marsden360 to become a standard part of lung cancer diagnosis, offering patients “the benefits of earlier diagnosis and treatment.”
Revolutionizing Lung Cancer Care
The minimally invasive Marsden360 liquid biopsy test offers a promising future for lung cancer patients. This innovative approach has the potential to revolutionize care, leading to faster diagnoses, personalized treatments, and improved outcomes for thousands.
Posted April 2024.
Subscribe to our newsletter
Personalised by your preferences, subscribe to our newsletters to get the best of the Pharmaceutical Industry news in your inbox.